Compare Biogen Inc (BIIB) vs Grab Holdings Ltd. (GRAB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs Grab Holdings Ltd. — how do they compare? Biogen Inc trades at $204 (market cap $30.13B), while Grab Holdings Ltd. trades at $3.73 (market cap $15.26B). The key difference: Biogen Inc is the larger of the two by market cap, and Biogen Inc is trading nearer its 52-week high, Grab Holdings Ltd. nearer its low. Which is the better fit depends on your goals.
| BIIB | GRAB | |
|---|---|---|
Market Cap | $30.13B | $15.26B |
Sector | Health | Technology |
52-Week High | $216.63 | $6.45 |
52-Week Low | $128.93 | $3.27 |
Enterprise Value | $37.20B | $10.99B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
GRAB trades at $3.67, up 0.27% today, with a bullish technical signal from moving averages and strong earnings beats in recent quarters. Revenue grew to $3.37B in 2025, with net income turning positive at $268M, reflecting improved profitability. The company raised its 2026 guidance after Q2 results, driven by on-demand and financial services growth. Analyst consensus is strongly bullish with an average price target of $5.86, implying 58% upside.
The outlook is positive given consistent earnings outperformance and raised guidance, but risks include high valuation (P/E 34), insider selling, and projected negative cash flow in 2026. Investors should weigh growth momentum against execution challenges in competitive Southeast Asian markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About Grab Holdings Ltd.
Grab Holdings Limited operates as a holding company. The Company, through its subsidiaries, develops delivery management, mobility, financial services, and enterprise software solutions. Grab Holdings serves customers worldwide.
Read more on GRAB →
